ArticleJournal of thoracic disease2026
Development and validation of prediction model for intrapulmonary metastasis in lung adenocarcinoma based on machine learning.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is a leading cause of cancer-related death, with intrapulmonary metastasis (IPM) delaying diagnosis and worsening prognosis. Despite machine learning (ML)'s promise in metastasis prediction, specific models for LUAD-IPM are lacking. The present study aimed to construct a ML algorithm to accurately predict the risk of IPM in patients with LUAD. Methods: We analyzed 61,519 LUAD patients diagnosed between 2018 and 2022 from the Surveillance, Epidemiology, and End Results (SEER) database, including 7,696 with IPM. Thirteen clinicopathological and demographic variables were assessed, covering demographics (age, sex, marital status, race), tumor features [size, primary site, tumor stage (T stage), node stage (N stage), bone/brain/liver/lung metastasis], and treatments (radiotherapy, chemotherapy). After excluding patients with missing key data, univariate and multivariate logistic regression (LR) identified independent prognostic factors (P<0.05). The Synthetic Minority Oversampling Technique (SMOTE) addressed class imbalance, and the balanced dataset was split into training (70%) and testing (30%) sets. Twelve ML models were constructed, with 10-fold cross-validation, calibration curves, and decision curve analysis (DCA) for validation. SHapley Additive exPlanations (SHAP) analysis quantified feature contributions and enhanced model interpretability. Results: T stage, N stage, bone/brain/liver metastasis, radiation, and chemotherapy were independent prognostic factors. The light gradient boosting machine (LGBM) model outperformed others, achieving a testing cohort area under the receiver operating characteristic (ROC) curve (AUC) of 0.818, sensitivity 0.782, specificity 0.717, and F1-score 0.421. SHAP analysis confirmed T stage, radiation, and N stage as the top 3 influential features shaping predictions. Conclusions: This is the first ML model specifically predicting LUAD-IPM. The LGBM model enables accurate risk stratification, supporting personalized surveillance and treatment optimization to improve clinical outcomes by identifying high-risk patients and avoiding unnecessary interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.